Chengdu Kanghong's KH815 enters human testing this month.

A biliary tract cancer trial hits on response rate, but survival data will be key.

Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.

AACR approaches, along with ASCO abstract titles.

As the non-muscle invasive space is carved up, Aura tries to seize part of it.

Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.